Public Health

Turn longevity from trend to strategy: where should pharma play - and how to win?

Despite media discussions around the drugs, only around a third across 30 countries have heard about the drugs, with a lot of the discourse taking place via social media according to the Ipsos Health Service Report.

Read our new viewpoint and delve into the paradox of early cancer detection: how expanding screening methods – particularly multi-cancer early detection tests – while life-saving, pose considerations such as psychological impacts, false positives, and ethical dilemmas.

Amidst global temperature rise concerns, Ipsos uncovers declining individual action despite heightened awareness. Spanning 32 countries, our report reveals regional differences in climate policy expectations and economic apprehensions, providing a roadmap for strategic climate engagement.

New Ipsos survey conducted across six countries reveals that despite 84% claiming to be sufficiently informed on the cardiac health, only less than a half are.

Melissa Dunne breaks down some hard-won insights half a decade after the COVID-19 pandemic sent the world into hard lockdown.

ASAP FOR CHILDREN has published the results of its third European Rare Disease Observatory conducted by Ipsos.

The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.

Across 31 countries 44% rate the quality of the healthcare they receive as good, but access to treatment and not enough staff are seen as major systemic challenges